Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Over the last decade, a vast panorama of evidence on the benefit–risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM). In this a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Endocrinol
Main Authors: Mathieu, Chantal, Kozlovski, Plamen, Paldánius, Päivi M, Foley, James E, Modgill, Vikas, Evans, Marc, Serban, Carmen
Formato: Artigo
Idioma:Inglês
Publicado em: Touch Medical Media 2017
Assuntos:
Type 2 Diabetes
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813467/
https://ncbi.nlm.nih.gov/pubmed/29632610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.68
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados